 | ||
 |
 |
 |
 |
 |
 |
|
Press releases
Kane Biotech has Been Selected as one of Canada's Top 10™ Emerging Life Sciences Companies
September 30, 2008
DispersinB® Trademark Registered in North America and Europe
September 17, 2008
Clinical Grade DispersinB™ has been Successfully Manufactured
September 9, 2008
"The Economic Report" to Feature Kane Biotech Inc.
September 2, 2008
Kane Biotech Enters into Material transfer and evaluation agreement with Ward Industries Group
July 22 , 2008
Key Milestone Met in DispersinB™ Manufacturing Process
July 7 , 2008
A New Study Shows DispersinB™ Helps our Body's Immune Cells to Kill Bacteria
July 2 , 2008
Kane Biotech Receives Notice of Allowance for DispersinB™ as a Registered Trademark
June 25 , 2008
Kane Biotech Retains BioVectra to Manufacture DispersinB™
March 4 , 2008
Kane Biotech Announces the Closing of a $1,550,000 Private Placement Offering
February 28 , 2008
Kane Biotech Announces Increase to Private Placement Offering
February 20 , 2008
Journal of Antimicrobial Chemotherapy Publishes Paper on Kane Biotech's PS/CHX Coating for Medical Devices
February 13 , 2008
Kane Biotech Announces Private Placement Offering
February 12 , 2008
Kane Biotech Awarded U.S. Patent for Compositions and Methods to Inhibit Biofilm Formation
January 23, 2008
DispersinB™ Biofilm Patent Issued in the United States
November 13, 2007
Kane Biotech Announces New Chief Financial Officer
October 30, 2007
Kane Biotech Invited to Present at the BioInterface 2007 Conference
October 15, 2007
Kane Biotech releases a report from recent research on the ability of DispersinB™ to Combat Biofilms and its application in wound care
September 4, 2007
Kane Biotech closes private placement
August 16, 2007
DispersinB™ for treating antibiotic resistant swine pleuropneumoniae
July 30, 2007
Kane Biotech announces private placement offering
July 12, 2007
Kane Biotech announces positive results from an independent wound care study
July 11, 2007
Kane Biotech announces a positive independent research publication on its DispersinB technology
June 18, 2007
Kane Biotech appoints Chief Scientific Officer and Cheif Executive Officer
May 23, 2007
Kane Biotech awarded patent for compositions and methods to inhibit biofilm formation
May 14, 2007
Kane Biotech and Harland Medical Systems Announce Commercial License Agreement
April 18, 2007
Kane Biotech Appoints Vice President of Research
February 8, 2007
Kane Biotech receives United States patent for methods of reducing
biofilm formation
January 23, 2007
Kane Biotech Introduces Investor Relations Professional
January 8, 2007
Kane Biotech Announces New Publication of Scientific Results
December 18, 2006
Kane Biotech Announces Positive Results of Central Venous Catheter Study
October 16, 2006
Kane Biotech Enters Study with KBI-4258
September 7, 2006
Kane Biotech Identifies Lead Candidate for Coating Central Venous Catheters
August 24, 2006
Kane Biotech Announces Publication of Scientific Discoveries
August 3, 2006
Kane Biotech Announces Closing of Private Placement Offering
May 30, 2006
Kane Biotech Announces Increase to Private Placement Offering
May 26, 2006
Kane Biotech Announces Amendment to Private Placement Offering
May 10, 2006
Kane Biotech Announces Private Placement of Up To $1,200,000
April 20, 2006
Kane Biotech Appoints New President
March 22, 2006
Kane Biotech Announces Positive Results for Lead Product in Urinary Catheter Study
November 23, 2005
Kane Biotech Recieves Key U.S. Patent for the Treatment of Dental Cavities
November 9, 2005
Kane Biotech Selects KBI-5898 as its Lead Product for Coating Urinary Catheters
October 18, 2005
Kane Biotech Announces Director Resignation
July 4, 2005
Kane Biotech Acquires Novel Product to Combat Biofilms
April 26, 2005
Kane Biotech Appoints New Executives
February 2, 2005
Kane Biotech Acquires Rights to Novel Biofilm Technology From the University of Toronto
January 25, 2005
Kane Biotech Closes Private Placement
January 20, 2005
Kane Biotech Insiders to Participate in Private Placement
December 7, 2004
Kane Biotech Announces Private Placement of up to $1,200,000
December 6, 2004
Kane Biotech Appoints Dr. Dennis Cvitkovitch to its Scientific Advisory Board
June 17, 2004
Kane Biotech Appoints Dr. Geoffrey Grant to its Board of Directors
January 27, 2004
New Trading Symbol TSXV:KNE
October 1, 2003
Kane Biotech Inc. Acquired by Vinson Biotech Inc.
September 25, 2003
